Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group.
Kudo K, Kojima S, Tabuchi K, Yabe H, Tawa A, Imaizumi M, Hanada R, Hamamoto K, Kobayashi R, Morimoto A, Nakayama H, Tsuchida M, Horibe K, Kigasawa H, Tsukimoto I; Japanese Childhood AML Cooperative Study Group. Kudo K, et al. Among authors: nakayama h. J Clin Oncol. 2007 Dec 1;25(34):5442-7. doi: 10.1200/JCO.2007.12.3687. J Clin Oncol. 2007. PMID: 18048827 Clinical Trial.
Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M, Yabe H, Nakayama H, Kudo K, Kobayashi R, Hamamoto K, Imaizumi M, Morimoto A, Tsuchiya S, Hanada R. Tsukimoto I, et al. Among authors: nakayama h. J Clin Oncol. 2009 Aug 20;27(24):4007-13. doi: 10.1200/JCO.2008.18.7948. Epub 2009 Jul 20. J Clin Oncol. 2009. PMID: 19620491
Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children.
Tomizawa D, Tawa A, Watanabe T, Saito AM, Kudo K, Taga T, Iwamoto S, Shimada A, Terui K, Moritake H, Kinoshita A, Takahashi H, Nakayama H, Koh K, Kigasawa H, Kosaka Y, Miyachi H, Horibe K, Nakahata T, Adachi S. Tomizawa D, et al. Among authors: nakayama h. Leukemia. 2013 Dec;27(12):2413-6. doi: 10.1038/leu.2013.153. Epub 2013 May 16. Leukemia. 2013. PMID: 23677335 No abstract available.
Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Tomizawa D, Tawa A, Watanabe T, Saito AM, Kudo K, Taga T, Iwamoto S, Shimada A, Terui K, Moritake H, Kinoshita A, Takahashi H, Nakayama H, Kiyokawa N, Isoyama K, Mizutani S, Hara J, Horibe K, Nakahata T, Adachi S. Tomizawa D, et al. Among authors: nakayama h. Int J Hematol. 2013 Nov;98(5):578-88. doi: 10.1007/s12185-013-1429-2. Epub 2013 Sep 26. Int J Hematol. 2013. PMID: 24068655 Free PMC article.
Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol.
Nakayama H, Tabuchi K, Tawa A, Tsukimoto I, Tsuchida M, Morimoto A, Yabe H, Horibe K, Hanada R, Imaizumi M, Hayashi Y, Hamamoto K, Kobayashi R, Kudo K, Shimada A, Miyamura T, Moritake H, Tomizawa D, Taga T, Adachi S. Nakayama H, et al. Int J Hematol. 2014 Aug;100(2):171-9. doi: 10.1007/s12185-014-1616-9. Epub 2014 Jun 25. Int J Hematol. 2014. PMID: 24961644
Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Matsuo H, Kajihara M, Tomizawa D, Watanabe T, Saito AM, Fujimoto J, Horibe K, Kodama K, Tokumasu M, Itoh H, Nakayama H, Kinoshita A, Taga T, Tawa A, Taki T, Tanaka S, Adachi S. Matsuo H, et al. Among authors: nakayama h. Blood Cancer J. 2014 Jul 11;4(7):e226. doi: 10.1038/bcj.2014.47. Blood Cancer J. 2014. PMID: 25014773 Free PMC article.
EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia.
Matsuo H, Kajihara M, Tomizawa D, Watanabe T, Saito AM, Fujimoto J, Horibe K, Kodama K, Tokumasu M, Itoh H, Nakayama H, Kinoshita A, Taga T, Tawa A, Taki T, Shiba N, Ohki K, Hayashi Y, Yamashita Y, Shimada A, Tanaka S, Adachi S. Matsuo H, et al. Among authors: nakayama h. Haematologica. 2014 Nov;99(11):e225-7. doi: 10.3324/haematol.2014.107128. Epub 2014 Jul 11. Haematologica. 2014. PMID: 25015941 Free PMC article. No abstract available.
Adverse prognostic impact of KIT mutations in childhood CBF-AML: the results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial.
Tokumasu M, Murata C, Shimada A, Ohki K, Hayashi Y, Saito AM, Fujimoto J, Horibe K, Nagao M, Itoh H, Kamikubo Y, Nakayama H, Kinoshita A, Tomizawa D, Taga T, Tawa A, Tanaka S, Heike T, Adachi S. Tokumasu M, et al. Among authors: nakayama h. Leukemia. 2015 Dec;29(12):2438-41. doi: 10.1038/leu.2015.121. Epub 2015 May 15. Leukemia. 2015. PMID: 25975190 No abstract available.
3,225 results